---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-060702"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:45:35.427029+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica reports FY 2022 net loss $24.5M; VP-102 PDUFA set for July 23, 2023

## Summary
- Net loss of $24.5M ($0.72/share) for FY 2022 vs $35.1M ($1.30/share) in FY 2021.
- Collaboration revenue of $9.0M in FY 2022, down from $12.0M in FY 2021.
- Cash and equivalents $34.3M at Dec 31, 2022; raised $32.5M gross in Feb 2023 secondary offering.
- FDA assigned PDUFA date of July 23, 2023 for VP-102 NDA for molluscum contagiosum.
- VP-315 Phase 2 Part 2 dosing expected to begin in Q2 2023 for basal cell carcinoma.

## SEC filing metadata
- accession: 0001193125-23-060702
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/0001193125-23-060702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/d474665d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-060702
- JSON: https://secwatch.observer/filing/0001193125-23-060702.json
- Plain text: https://secwatch.observer/filing/0001193125-23-060702.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 6, 2023, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/0001193125-23-060702-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.